Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,General Medicine
Reference19 articles.
1. Amin A, Stokes M, Makenbaeva D, Wiederkehr D, Wu N, Lawrence JH (2014) Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. J Med Econ. 17:771–781
2. Anguita Sánchez M, Bertomeu Martínez V, Ruiz Ortiz M, Cequier Fillat Á, Roldán Rabadán I, Muñiz García J, Badimón Maestro L, Esteve Pastor MA, Marín Ortuño F, FANTASIIA study investigators (2020) Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study. Rev Esp Cardiol. 73:14–20
3. Athanasakis K, Boubouchairopoulou N, Karampli E, Tarantilis F, Savvari P, Bilitou A, Kyriopoulos J (2017) Cost effectiveness of apixaban versus warfarin or aspirin for stroke prevention in patients with atrial fibrillation: a Greek perspective. Am J Cardiovasc Drugs. 17:123–133
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (2009) RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 361:1139–1151
5. European Medicines Agency (EMA). Eudravigilance Expert Working Group (EV-Ewg) (2006) Guideline on the use of statistical signal detection methods in the eudravigilance data analysis system. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011437.pdf.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献